China-based Aucta Pharmaceuticals has submitted a listing application to the Hong Kong Stock Exchange (HKEX). Founded in 2012, the company is a research-driven pharmaceutical firm focused on developing improved formulations of known molecules, with a primary focus on central nervous system (CNS) disorders, metabolic diseases and rare conditions. Aucta operates dual R&D and production centres in Shanghai and the US, utilising three proprietary drug delivery platforms for paediatric, controlled-release, and nasal formulations.

The company's pipeline comprises 15 projects, including key asset AUC059, a GLP-1 receptor agonist nasal spray. Aucta claims to be the first company globally to clinically develop a nasal GLP-1 product and plans to initiate a Phase III trial for AUC059 in November 2026. Financially, Aucta reported revenues of RMB 292 million (USD 40.7 million) for 2024 and RMB 186 million (USD 25.9 million) for the first nine months of 2025, with a net profit of RMB 7.1 million (USD 1.0 million) and a net loss of RMB 40.1 million (USD 5.6 million) for the respective periods.

According to PharmCube's MedAlpha® database, Aucta has carried out four pre-IPO funding rounds. Click here to request a free trial for MedAlpha®.